BELLUS Health Inc News - BLU | ADVFN

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

Home
Investing
Stocks
Canada
TSX
BELLUS Health Inc (BLU)
BELLUS Health Inc (BLU) News

BELLUS Health Inc (BLU)

19.48

0.00

(0.00%)

Closed April 14 4:12PM

Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Annonce boursière - Réservée aux médias et aux investisseurs - GSK mène à terme l'acquisition de BELLUS Santé

Annonce boursière - Réservée aux médias et aux investisseurs - GSK mène à terme l'acquisition de BELLUS...

Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health

Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health Canada NewsWire LONDON, June 28, 2023...

S&P Dow Jones Indices annonce des modifications à l'indice composé S&P/TSX et à l'indice S&P/TSX 60

S&P Dow Jones Indices annonce des modifications à l'indice composé S&P/TSX et à l'indice S&P/TSX 60 Canada...

S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index and S&P/TSX 60 Index

S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index and S&P/TSX 60 Index Canada NewsWire TORONTO, Sept. 2, 2022...

BELLUS Santé présentera les plus récentes données cliniques de l’essai SOOTHE de phase 2b du BLU‑5937 à la ATS 2022 International Conference

BELLUS Santé inc. (Nasdaq : BLU; TSX : BLU) (« BELLUS Santé » ou la « société »), une société biopharmaceutique au stade clinique qui développe...

BELLUS Health to Participate in Multiple Upcoming Investor Conferences

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel...

BELLUS Santé participera à la Cowen & Co. 42nd Annual Health Care Conference

BELLUS Santé inc. (Nasdaq : BLU; TSX : BLU) (« BELLUS Santé » ou la « société »), une société biopharmaceutique au stade clinique qui développe...

BELLUS Santé annonce ses résultats financiers et faits saillants pour l’exercice 2021

- Annonce des résultats principaux positifs de l’essai clinique SOOTHE de phase 2b pour le traitement de la toux chronique réfractaire qui...

BELLUS Santé mène à terme un placement public de 200 M$ US d’actions ordinaires au Canada et aux États‑Unis

BELLUS Santé inc. (NASDAQ : BLU) (TSX : BLU) (la « Société» ou « BELLUS Santé ») a annoncé aujourd’hui qu’elle a mené à terme son placement...

BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States

Common Shares Priced at US$8.00 per Share In connection with its previously announced public offering of common shares in Canada and the United...

1
Next

Rendering Error

Error: 507

mik1234

mik1234 4 years ago

it was a good day $$ BLU

Oliverjack

Oliverjack 5 years ago

insider bought 260k worth today monday 13th lol

Bottom Feedr

Bottom Feedr 5 years ago

Massive drop and ceo buys more! Hmmnnnn

Bottom Feedr

Bottom Feedr 5 years ago

Wake up sleepy head time to rock the market!

dalesio_98

dalesio_98 6 years ago

RichardSawars

RichardSawars 6 years ago

TrendTrade2016

TrendTrade2016 7 years ago

BLU.TO hot canadian bio

TrendTrade2016

TrendTrade2016 7 years ago

BLU is a beast!!

TrendTrade2016

TrendTrade2016 7 years ago

The BLU beast!!

TrendTrade2016

TrendTrade2016 7 years ago

put out a call on BLU.TO a monster bio play!!

xr_biotech_consult

xr_biotech_consult 9 years ago

happy to sold nearly 8000 during last days...only 4000 left for sale today.

xr_biotech_consult

xr_biotech_consult 9 years ago

2.99 weeeeEEEE°°

xr_biotech_consult

xr_biotech_consult 9 years ago

what shoud i say? 2.32 !!

xr_biotech_consult

xr_biotech_consult 9 years ago

xr_biotech_consult

xr_biotech_consult 9 years ago

yessss..new high..1.92

xr_biotech_consult

xr_biotech_consult 9 years ago

great Chart.. crushed 1,75 good sign. more will come

xr_biotech_consult

xr_biotech_consult 9 years ago

pivotal Phase 3 trail completed, top line results expected q2, fast track by FDA, rare desease, Long patent protection, Peak sales expected -1b ! ongoing Pipeline with rare deseases.. still great opportunity here

xr_biotech_consult

xr_biotech_consult 9 years ago

xr_biotech_consult

xr_biotech_consult 9 years ago

hrhr here weee goo

xr_biotech_consult

xr_biotech_consult 9 years ago

expected Prices per Patient per year 200-275 Thousand

xr_biotech_consult

xr_biotech_consult 9 years ago

Peak sales expected 600m - 1b
http://www.bellushealth.com/English/investors-and-news/presentations/default.aspx

xr_biotech_consult

xr_biotech_consult 9 years ago

xr_biotech_consult

xr_biotech_consult 10 years ago

will move up again

xr_biotech_consult

xr_biotech_consult 11 years ago

target 2.50 CAD

xr_biotech_consult

xr_biotech_consult 11 years ago

yea hell great, new high hunts new high

xr_biotech_consult

xr_biotech_consult 11 years ago

BLU out in the blue

xr_biotech_consult

xr_biotech_consult 11 years ago

waht did i told u

xr_biotech_consult

xr_biotech_consult 11 years ago

massive breakout will come here

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions